Tirzepatide for Weight Loss: Complete Patient Guide
Everything you need to know about tirzepatide — how its dual GIP/GLP-1 mechanism works, what the SURMOUNT trials show, who qualifies, and how to access physician-supervised treatment.
· DietsMD Editorial Team · 14 min read
Medically reviewed by DietsMD Board-Certified Physicians specializing in obesity medicine and metabolic health.
Quick Answer
Tirzepatide is an FDA-approved dual GIP/GLP-1 receptor agonist for chronic weight management (brand name Zepbound®). In the SURMOUNT-1 trial, patients lost an average of 20.9% of body weight at the 15 mg dose over 72 weeks — the highest average weight loss ever recorded in a weight loss medication trial.
What Is Tirzepatide?
Tirzepatide is a first-in-class dual GIP and GLP-1 receptor agonist developed by Eli Lilly. It was originally approved as Mounjaro® for type 2 diabetes in 2022 and received FDA approval as Zepbound® for chronic weight management in November 2023.
How Tirzepatide Works: The Dual Mechanism
GLP-1 Receptor Agonism
- Appetite suppression: Reduces hunger signals in the hypothalamus
- Slowed gastric emptying: Prolongs satiety after meals
- Insulin stimulation: Glucose-dependent insulin secretion and glucagon suppression
GIP Receptor Agonism — The Differentiator
- Enhanced insulin secretion: GIP amplifies the insulin response to meals
- Improved fat metabolism: GIP receptors in adipose tissue enhance fat breakdown
- Additional appetite regulation: GIP acts on brain reward pathways
- Synergistic weight loss: Combined GIP + GLP-1 produces greater weight loss than either alone
Tirzepatide Clinical Trial Results
SURMOUNT-1 Trial
- Participants: 2,539 adults with obesity or overweight with a weight-related condition, without type 2 diabetes
- Duration: 72 weeks
- 5 mg dose: avg. weight loss 15.0%
- 10 mg dose: avg. weight loss 19.5%
- 15 mg dose: avg. weight loss 20.9%
- 37% of participants at 15 mg lost ≥25% of body weight
SURMOUNT-2 (Type 2 Diabetes)
- Average weight loss of 15.7% at 15 mg over 72 weeks in patients with obesity and type 2 diabetes
SURMOUNT-4 (Discontinuation)
- Patients who stopped tirzepatide regained approximately two-thirds of lost weight within 52 weeks, confirming the need for long-term treatment
Tirzepatide Dosing and Administration
| Week | Dose | Purpose |
|---|---|---|
| Weeks 1–4 | 2.5 mg/week | Initiation |
| Weeks 5–8 | 5 mg/week | Dose escalation |
| Weeks 9–12 | 7.5 mg/week | Dose escalation |
| Weeks 13–16 | 10 mg/week | Dose escalation |
| Weeks 17–20 | 12.5 mg/week | Dose escalation |
| Week 21+ | 15 mg/week | Maintenance dose (target) |
Potential Benefits of Tirzepatide
- Highest average weight loss of any FDA-approved weight loss medication (~20–22%)
- Significant improvements in blood sugar control and HbA1c
- Reduced blood pressure and improved lipid profiles
- Reduced appetite and food cravings
- Once-weekly dosing for convenience
- Effective for patients with and without type 2 diabetes
Side Effects and Safety
Common Side Effects
- Nausea — most common, especially during dose escalation
- Vomiting, diarrhea, constipation, abdominal discomfort
- Fatigue, injection site reactions
Serious Risks (Rare)
- Thyroid C-cell tumors: Boxed warning for patients with history of MTC or MEN2
- Pancreatitis: Rare; discuss history with physician
- Gallbladder disease: Rapid weight loss can increase gallstone risk
Who Qualifies for Tirzepatide?
- BMI of 30 or greater (obesity), OR
- BMI of 27 or greater with at least one weight-related condition
- No personal or family history of MTC or MEN2
- Not pregnant or planning to become pregnant
Find Out If Tirzepatide Is Right for You
DietsMD board-certified physicians evaluate your health history and prescribe tirzepatide when clinically appropriate. Discreet home delivery. Ongoing physician support.
How to Get Tirzepatide Online
- Complete a medical intake form. Provide your health history, medications, weight history, and goals.
- Physician consultation. A board-certified physician reviews your intake and determines whether tirzepatide is appropriate.
- Prescription issued. Sent to a licensed U.S. pharmacy.
- Discreet home delivery. Shipped directly to your home.
- Ongoing monitoring. Regular physician check-ins throughout treatment.
Brand-Name vs. Compounded Tirzepatide
- Brand-name Zepbound®: FDA-approved, manufactured by Eli Lilly. May be covered by some insurance plans.
- Compounded tirzepatide: Prepared by licensed U.S. compounding pharmacies (503A or 503B). Legal when prescribed by a licensed physician. Always confirm accreditation.
Tirzepatide vs. Semaglutide: Which Is Right for You?
Both tirzepatide and semaglutide are FDA-approved GLP-1 medications for weight loss. Tirzepatide has demonstrated greater average weight loss (~20–22% vs ~15%), but semaglutide has a longer track record and established cardiovascular benefit data from the SELECT trial.
Read our full GLP-1 weight loss guide or explore top online medical weight loss programs to learn more.
Frequently Asked Questions About Tirzepatide
Tirzepatide is a dual GIP/GLP-1 receptor agonist used for type 2 diabetes (Mounjaro) and chronic weight management (Zepbound). It produces approximately 20-22% average body weight loss in clinical trials.
In SURMOUNT-1, participants lost an average of 20.9% of body weight at the 15 mg dose over 72 weeks. 37% lost 25% or more. Individual results vary.
Tirzepatide produces greater average weight loss (~20-22% vs ~15%). Semaglutide has a longer track record and established cardiovascular benefit data. The best choice depends on your health history and physician recommendation.
Yes. SURMOUNT-4 showed patients regained approximately two-thirds of lost weight within 52 weeks of stopping. Long-term treatment is typically recommended.
Yes. Licensed telehealth platforms like DietsMD allow patients to consult with physicians online, receive a prescription, and have medication delivered home. A physician evaluation is required.
Both contain tirzepatide at the same dose range. Mounjaro is for type 2 diabetes. Zepbound is for chronic weight management.
Tirzepatide is contraindicated in patients with a personal or family history of medullary thyroid carcinoma or MEN2. Pregnant patients should not use it.
